Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

NICE guidance on azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia, and acute myeloid leukaemia.

Miller W, Holden J, George E, Stein K.

Lancet Oncol. 2011 Apr;12(4):326-7. No abstract available.

PMID:
21598446
2.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

PMID:
20507806
3.

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.

Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.

Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.

4.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
5.

Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.

Niscola P, Tendas A, Cupelli L, Giovannini M, Piccioni D, Scaramucci L, Dentamaro T, Del Poeta G, de Fabritiis P.

Acta Haematol. 2015;133(1):64-6. doi: 10.1159/000363643. Epub 2014 Aug 14. No abstract available.

PMID:
25139255
6.

Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.

Meers S, Selleslag D, Potier H, Glasmacher A, Mineur P, Voelter V.

Curr Med Res Opin. 2015 Jan;31(1):35-42. doi: 10.1185/03007995.2014.972499. Epub 2014 Oct 17.

PMID:
25317956
7.

Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.

Alhan C, Westers TM, van der Helm LH, Eeltink C, Huls G, Witte BI, Buchi F, Santini V, Ossenkoppele GJ, van de Loosdrecht AA.

Cytometry B Clin Cytom. 2014 May;86(3):207-15. doi: 10.1002/cyto.b.21160. Epub 2014 Jan 28.

8.

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

Müller-Thomas C, Rudelius M, Rondak IC, Haferlach T, Schanz J, Huberle C, Schmidt B, Blaser R, Kremer M, Peschel C, Germing U, Platzbecker U, Götze K.

Haematologica. 2014 Oct;99(10):e179-81. doi: 10.3324/haematol.2014.104760. Epub 2014 Jun 27. No abstract available.

9.

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B.

J Clin Oncol. 2011 Jun 20;29(18):2521-7. doi: 10.1200/JCO.2010.34.4226. Epub 2011 May 16.

10.

Concise drug review: azacitidine and decitabine.

Derissen EJ, Beijnen JH, Schellens JH.

Oncologist. 2013;18(5):619-24. doi: 10.1634/theoncologist.2012-0465. Epub 2013 May 13. No abstract available.

11.

[5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].

Gao S, Hu XH, Qiu HY, Xu Y, Jin ZM, He GS, Tang XW, Han Y, Chen SN, Sun AN, Wu DP.

Zhonghua Xue Ye Xue Za Zhi. 2013 Jun;34(6):542-3. doi: 10.3760/cma.j.issn.0253-2727.2013.06.019. Chinese. No abstract available.

PMID:
23827117
12.

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.

Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schönefeldt C, Shirneshan K, Röllig C, Bornhäuser M, Naumann R, Neesen J, Giagounidis A, Hofmann WK, Ehninger G, Germing U, Haase D, Wermke M.

Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28. No abstract available.

13.

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

Laille E, Shi T, Garcia-Manero G, Cogle CR, Gore SD, Hetzer J, Kumar K, Skikne B, MacBeth KJ.

PLoS One. 2015 Aug 21;10(8):e0135520. doi: 10.1371/journal.pone.0135520. eCollection 2015.

14.

Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.

Infante MS, Muñoz C, Heras C, Foncillas MA, González I, Lucea I, Echavarria E, Aramendi T, Hernández JA.

Eur J Dermatol. 2015 Nov-Dec;25(6):622-3. doi: 10.1684/ejd.2015.2661. No abstract available.

PMID:
26552844
15.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
16.

Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Zeidan AM, Lee JW, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD.

Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.

17.

Patterns of infection in patients with myelodysplastic syndromes and acute myeloid leukemia receiving azacitidine as salvage therapy. Implications for primary antifungal prophylaxis.

Falantes JF, Calderón C, Márquez-Malaver FJ, Aguilar-Guisado M, Martín-Peña A, Martino ML, Montero I, González J, Parody R, Pérez-Simón JA, Espigado I.

Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):80-6. doi: 10.1016/j.clml.2013.09.014. Epub 2013 Oct 1.

PMID:
24220615
18.

Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.

Villela L, Anders V, Bolaños-Meade J.

Anticancer Drugs. 2010 Apr;21(4):469. doi: 10.1097/CAD.0b013e328335be46. No abstract available.

PMID:
20216343
19.

Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

Prebet T, Sun Z, Figueroa ME, Ketterling R, Melnick A, Greenberg PL, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Litzow M, Gabrilove J, Erba HP, Gore SD, Tallman MS.

J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24.

20.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

Supplemental Content

Support Center